News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,444 Results
Type
Article (14053)
Company Profile (283)
Press Release (249108)
Section
Business (79426)
Career Advice (152)
Deals (13212)
Drug Delivery (34)
Drug Development (50383)
Employer Resources (31)
FDA (5698)
Job Trends (5120)
News (144249)
Policy (10022)
Tag
Academia (901)
Alliances (21590)
Alzheimer's disease (783)
Antibody-drug conjugate (ADC) (70)
Approvals (5686)
Artificial intelligence (90)
Bankruptcy (99)
Best Places to Work (4550)
Biotechnology (232)
Breast cancer (123)
Cancer (1040)
Cardiovascular disease (84)
Career advice (132)
CAR-T (86)
Cell therapy (248)
Clinical research (40425)
Collaboration (400)
Compensation (155)
COVID-19 (1019)
C-suite (104)
Cystic fibrosis (72)
Data (1073)
Diabetes (98)
Diagnostics (1245)
Earnings (29085)
Events (47475)
Executive appointments (326)
FDA (6145)
Funding (379)
Gene editing (72)
Gene therapy (187)
GLP-1 (335)
Government (1069)
Healthcare (6560)
Infectious disease (1060)
Inflammatory bowel disease (100)
IPO (7233)
Job creations (859)
Job search strategy (127)
Layoffs (194)
Legal (1381)
Lung cancer (154)
Manufacturing (95)
Medical device (2566)
Medtech (2567)
Mergers & acquisitions (6185)
Metabolic disorders (298)
Neuroscience (1078)
NextGen: Class of 2025 (2013)
Non-profit (851)
Northern California (1243)
Obesity (162)
Opinion (93)
Parkinson's disease (86)
Patents (72)
People (25276)
Phase I (14272)
Phase II (18797)
Phase III (11886)
Pipeline (462)
Postmarket research (852)
Preclinical (5984)
Radiopharmaceuticals (208)
Rare diseases (231)
Real estate (1411)
Regulatory (8380)
Research institute (932)
Series A (75)
Southern California (1115)
Startups (1968)
United States (9847)
Vaccines (177)
Weight loss (94)
Date
Today (47)
Last 7 days (379)
Last 30 days (1600)
Last 365 days (20425)
2025 (1607)
2024 (20553)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11848)
2015 (14352)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17040)
Australia (2883)
California (2838)
Canada (895)
China (255)
Colorado (106)
Connecticut (118)
Delaware (65)
Europe (36657)
Florida (320)
Georgia (84)
Illinois (180)
Indiana (69)
Maryland (371)
Massachusetts (2249)
Minnesota (113)
New Jersey (707)
New York (781)
North Carolina (450)
Northern California (1243)
Ohio (91)
Pennsylvania (536)
South America (207)
Southern California (1115)
Texas (316)
Washington State (272)
263,444 Results for "vesigen therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Vesigen to Present at the 2024 Cell and Gene Meeting on the Med
Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.
April 3, 2024
·
1 min read
Genetown
Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting
Vesigen Therapeutics, Inc. today announced that the Company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
May 1, 2024
·
2 min read
Genetown
Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting
Vesigen Therapeutics, Inc. today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
April 22, 2024
·
3 min read
Genetown
Vesigen Highlights Key in vivo and Targeted Tropism Data Advancements for Non-Viral Delivery Platform at 2024 ASGCT and ARVO Annual Meetings
Vesigen Therapeutics, Inc. recently showcased two data presentations at the Association for Research in Vision and Ophthalmology Annual Meeting and ten data presentations at the American Society of Gene & Cell Therapy Annual Meeting.
May 13, 2024
·
6 min read
Genetown
Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge
Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED Challenge.
December 19, 2023
·
2 min read
Genetown
Vesigen to Present at the 2023 Cell and Gene Meeting on the Mesa
Vesigen Therapeutics, Inc. today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2023 Cell and Gene Meeting on the Mesa on October 12 at 9:15 AM PT in Carlsbad, CA.
October 5, 2023
·
1 min read
Genetown
Vesigen Highlights New Data on Non-Viral Delivery Platform at the Exosome Based Therapeutic Development Summit
Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today showcased new data at the Exosome Based Therapeutic Development Summit 5th Annual Meeting held September 5-7, 2023 in Boston.
September 7, 2023
·
1 min read
Genetown
Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors In Vivo at the Cracking the Code: The Dawn of Nucleic Acid Medicines Meeting
Vesigen Therapeutics, Inc. presented data further highlighting the potential of the Company’s non-viral ARMM technology to deliver novel therapeutic payloads to cell and tissue types relevant to multiple therapeutic areas with high unmet need.
October 19, 2023
·
3 min read
Genetown
Vesigen Highlights Therapeutic Platform for Non-Viral Delivery of Gene Editors and RNA at ASGCT 2023
Vesigen Therapeutics, Inc showcased eight data presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting held May 16-20, 2023 in Los Angeles.
May 22, 2023
·
4 min read
Genetown
Vesigen Highlights Data Demonstrating Directed Tropism of Non-Viral Delivery Platform at the 30th Annual Congress of the European Society of Gene & Cell Therapy
Vesigen Therapeutics, Inc. today presented data highlighting the potential of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) technology to overcome fundamental delivery challenges that limit the clinical application of emerging treatment modalities.
October 25, 2023
·
3 min read
1 of 26,345
Next
